## Emanuela Vaccher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8801917/publications.pdf

Version: 2024-02-01

76 papers 3,183 citations

172386 29 h-index 54 g-index

79 all docs

79 docs citations

79 times ranked  $\begin{array}{c} 3857 \\ \text{citing authors} \end{array}$ 

#	Article	IF	CITATIONS
1	Hepatocellular carcinoma in HIV-infected patients. Aids, 2004, 18, 2285-2293.	1.0	213
2	Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood, 2005, 105, 1891-1897.	0.6	195
3	Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer, 2001, 91, 155-163.	2.0	181
4	Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood, 2002, $100$ , $1984$ - $1988$ .	0.6	156
5	AIDS-Related Kaposi's Sarcoma: Evaluation of Potential New Prognostic Factors and Assessment of the AIDS Clinical Trial Group Staging System in the Haart Eraâ€"the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naà ve From Antiretrovirals. Journal of Clinical Oncology, 2003. 21. 2876-2882.	0.8	150
6	Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus Type 8-Positive Solid Lymphomas. Journal of Molecular Diagnostics, 2005, 7, 17-27.	1.2	146
7	AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood, 2006, 107, 3832-3840.	0.6	133
8	High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood, 2009, 114, 1306-1313.	0.6	130
9	Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nature Reviews Clinical Oncology, 2014, 11, 223-238.	12.5	125
10	Lung carcinoma in 36 patients with human immunodeficiency virus infection., 2000, 88, 563-569.		119
11	Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer, 2003, 98, 2440-2446.	2.0	108
12	Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. Aids, 2000, 14, 1675-1688.	1.0	96
13	AIDS-Related Kaposis Sarcoma: State of the Art and Therapeutic Strategies. Current HIV Research, 2009, 7, 634-638.	0.2	82
14	Improvement of Systemic Human Immunodeficiency Virus-Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2003, 37, 1556-1564.	2.9	76
15	Tobacco smoking, alcohol drinking, and the risk of different histological types of nasopharyngeal cancer in a low-risk population. Oral Oncology, 2011, 47, 541-545.	0.8	70
16	Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Annals of Oncology, 2014, 25, 1059-1064.	0.6	67
17	A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2017, 28, 2820-2826.	0.6	66
18	Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: A comparative study. Human Pathology, 1996, 27, 133-146.	1.1	56

#	Article	IF	Citations
19	Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases. PLoS ONE, 2015, 10, e0117420.	1.1	54
20	The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy. Oral Oncology, 2017, 67, 175-182.	0.8	50
21	Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. Viruses, 2020, 12, 798.	1.5	46
22	Immune Recovery after Autologous Stem Cell Transplantation Is Not Different for HIVâ€Infected versus HIVâ€Uninfected Patients with Relapsed or Refractory Lymphoma. Clinical Infectious Diseases, 2010, 50, 1672-1679.	2.9	45
23	Consumption of fruit, vegetables, and other food groups and the risk of nasopharyngeal carcinoma. Cancer Causes and Control, 2013, 24, 1157-1165.	0.8	41
24	Clinical value of Epstein–Barr virus DNA levels in peripheral blood samples of Italian patients with Undifferentiated Carcinoma of Nasopharyngeal Type. Cancer Letters, 2006, 233, 247-254.	3.2	37
25	An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma. Clinical Cancer Research, 2017, 23, 3769-3780.	3.2	36
26	Rapid and sensitive analysis of vincristine in human plasma using onâ€ine extraction combined with liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 519-525.	0.7	35
27	Hematologic cancers in individuals infected by HIV. Blood, 2022, 139, 995-1012.	0.6	35
28	Interferon-Î <sup>3</sup> secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunology, Immunotherapy, 2003, 52, 28-32.	2.0	34
29	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. Journal of Endocrinological Investigation, 2020, 43, 337-345.	1.8	33
30	Prognostic significance of LINE-1 hypomethylation in oropharyngeal squamous cell carcinoma. Clinical Epigenetics, 2017, 9, 58.	1.8	32
31	KSHVâ€associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies. International Journal of Cancer, 2015, 137, 251-261.	2.3	31
32	Phase 2 study of intrathecal, longâ€acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virusâ€related nonâ€Hodgkin lymphoma. Cancer, 2010, 116, 1495-1501.	2.0	30
33	Human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer, 2001, 92, 200-206.	2.0	27
34	Increased cancer risk in patients undergoing dialysis: a population-based cohort study in North-Eastern Italy. BMC Nephrology, 2019, 20, 107.	0.8	24
35	Life Expectancy in the Immune Recovery Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 175-181.	0.9	23
36	Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. Nutrients, 2021, 13, 1277.	1.7	23

#	Article	IF	Citations
37	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2018, 73, 177-182.	1.3	22
38	Clinical Evaluation of 451 Patients with HIV Related Non-Hodgkin's Lymphoma: Experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). Leukemia and Lymphoma, 1995, 20, 91-96.	0.6	19
39	Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Cancer Immunology Research, 2016, 4, 431-440.	1.6	19
40	Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes. International Journal of Cancer, 2009, 125, 1358-1364.	2.3	18
41	Management of Immunocompetent Patients With Primary Central Nervous System Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 353-364.	1.4	18
42	The Evolving Scenario of Non-AIDS-Defining Cancers: Challenges and Opportunities of Care. Oncologist, 2014, 19, 860-867.	1.9	16
43	Estimating Minimum Adult HIV Prevalence: A Cross-Sectional Study to Assess the Characteristics of People Living with HIV in Italy. AIDS Research and Human Retroviruses, 2015, 31, 282-287.	0.5	16
44	HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2. Oncotarget, 2016, 7, 37487-37497.	0.8	16
45	Specific Antibodies Reacting with SV40 Large T Antigen Mimotopes in Serum Samples of Healthy Subjects. PLoS ONE, 2016, 11, e0145720.	1.1	15
46	Prognostic significance of neutrophilâ€toâ€lymphocyte ratio in HPV status era for oropharyngeal cancer. Oral Diseases, 2020, 26, 1384-1392.	1.5	15
47	Elderly Head and Neck (H-N) Cancer Patients: A Monoinstitutional Series. Tumori, 2002, 88, S63-S66.	0.6	14
48	Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. Journal of Clinical Virology, 2012, 53, 297-301.	1.6	14
49	Potential hazard drug–drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphoma. Aids, 2013, 27, 1033-1035.	1.0	13
50	Serologic investigation of undifferentiated nasopharyngeal carcinoma and simian virus 40 infection. Head and Neck, 2016, 38, 232-236.	0.9	13
51	Direct health-care cost of head and neck cancers: a population-based study in north-eastern Italy. Medical Oncology, 2019, 36, 31.	1.2	11
52	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology, 2019, 10, 475.	1.5	11
53	HAART Is Effective as Anti–Kaposi's Sarcoma Therapy Only After Remission Has Been Induced by Chemotherapy. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 407.	0.9	10
54	Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma. Oral Oncology, 2005, 41, 526-533.	0.8	10

#	Article	IF	Citations
55	Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes. European Archives of Oto-Rhino-Laryngology, 2009, 266, 719-726.	0.8	10
56	Alteration of G1/S transition regulators influences recurrences in head and neck squamous carcinomas. Journal of Cellular Physiology, 2012, 227, 233-238.	2.0	9
57	Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. Oncologist, 2020, 25, e1254-e1254.	1.9	8
58	Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. Aids, 2000, 14, 1457-1458.	1.0	8
59	Multiple preinvasive and invasive HPV-related lesions of the anogenital tract in a female patient with HIV infection. Medicine (United States), 2017, 96, e5948.	0.4	7
60	Immunodeficiency-associated Hodgkin lymphoma. Expert Review of Hematology, 2021, 14, 547-559.	1.0	7
61	Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB–IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. Oral Oncology, 2011, 47, 905-909.	0.8	6
62	Comment on  Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection'. British Journal of Cancer, 2012, 106, 1899-1900.	2.9	6
63	Autograft HIV-DNA Load Predicts HIV-1 Peripheral Reservoir After Stem Cell Transplantation for AIDS-Related Lymphoma Patients. AIDS Research and Human Retroviruses, 2015, 31, 150-159.	0.5	6
64	Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: A potential role of interleukin-7. Cytokine, 2012, 60, 90-95.	1.4	5
65	Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 180-186.	0.8	5
66	Simultaneous occurrence of KSHV-associated malignancies in a patient affected by HIV. Blood, 2021, 137, 3149-3149.	0.6	5
67	Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. Expert Review of Molecular Diagnostics, 2018, 18, 259-277.	1.5	4
68	Elderly head and neck (H-N) cancer patients: a monoinstitutional series. Tumori, 2002, 88, S63-6.	0.6	4
69	Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma. Oncotarget, 2015, 6, 30334-30342.	0.8	3
70	Evolving treatment implementation among HIV–infected pregnant women and their partners: results from a national surveillance study in Italy, 2001–2015. Journal of Global Health, 2017, 7, 010407.	1.2	2
71	Intensity-Modulated Radiotherapy with a Simultaneous Integrated Boost Combined with Chemotherapy in Stages III-IV Hypopharynx-Larynx Cancer: Treatment Compliance and Clinical Outcomes. Journal of Radiotherapy, 2014, 2014, 1-7.	0.2	1
72	Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA. Frontiers in Oncology, 2021, 11, 772348.	1.3	1

#	Article	IF	CITATIONS
73	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
74	IMRT with concomitant boost versus conventional radiation in the setting of sequential chemoradiotherapy for oropharyngeal cancer. Journal of Radiotherapy in Practice, 2014, 13, 418-427.	0.2	0
75	Neoplastic disease. , 2010, , 989-993.		O
76	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 226-241.	0.8	0